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Abstract
Expression and function of the human papillomavirus (HPV) early protein 6 (E6) is necessary for viral replication and
oncogenesis in cervical cancers. HPV E6 targets the tumor suppressor protein p53 for degradation. To achieve this,
“high-risk” HPV E6 proteins bind to and modify the target specificity of the ubiquitin ligase E6AP (E6 associated
protein). This E6-dependent loss of p53 enables the virus to bypass host cell defenses and facilitates virally induced
activation of the cell cycle progression during viral replication. Disruption of the interaction between E6 and E6AP and
stabilization of p53 should decrease viability and proliferation of HPV positive cells. A new in vitro high-throughput
binding assay was developed to assay binding between HPV-16 E6 and E6AP and to identify compounds that inhibit
this interaction. The compound luteolin emerged from the screen and a library of novel flavones based on its
structure was synthesized and characterized using this in vitro binding assay. The compounds identified in this study
disrupt the E6/E6AP interaction, increase the levels of p53 and p21Cip1/Waf1, and decrease proliferation of HPV positive
cell lines. The new class of flavonoid E6 inhibitors displays a high degree of specificity for HPV positive cells. Docking
analyses suggest that these compounds bind in a hydrophobic pocket at the interface between E6 and E6AP and
mimic the leucines in the conserved α-helical motif of E6AP. The activity and specificity of these compounds
represent a promising new lead for development as an antiviral therapy in the treatment of HPV infection and cervical
cancer.
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Introduction
HPV causes common cutaneous, mucosal, anogenital, and
oropharyngeal epithelial growths. Genital warts are highly
transmissible and affect all socioeconomic groups. The CDC
estimated there are ~750,000 new cases of genital warts each
year and 1.5 million persons under treatment in the USA.
Annually three million new cases of abnormal Pap smears are
detected in the USA, indicating active HPV infection. A minority
of these lesions progress to pre-cancerous dysplasia and to
invasive malignancy. On a worldwide basis, ~500,000 new
cases of cervical cancer are diagnosed and nearly 250,000
deaths occur each year. HPV type 16 is found in approximately
50% of all cervical cancers [1] and is the most frequent isolate
from oropharyngeal cancers, of which 25-50% are attributed to
HPV [2–4].
The HPV-E6 protein is essential for viral replication and
instrumental in bypassing host cell defenses and preventing
apoptosis [5–7]. The best-known function of HPV E6 is its
ability to target the tumor suppressor p53 for degradation. The
cervical cancer associated or “high-risk” HPV-E6 proteins
directly bind the ubiquitin ligase E6AP and targets p53 for
inactivation by inducing its degradation at the proteasome
[8–10]. p53 regulates cell growth and is the most commonly
mutated tumor suppressor gene in human malignancies
[11,12]. The E6 proteins from high-risk viruses are similar in
amino acid sequence, bind E6AP, and degrade p53. High-risk
HPV genomes with mutations in E6 that prevent p53
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degradation do not replicate in primary keratinocytes [13,14].
E6 binds to a conserved α-helical motif found in E6AP and
several other cellular factors [5,6,15–18]. E6 can also increase
telomerase activity and forestall replicative senescence [19,20].
Its C-terminal region binds to members of PDZ domain family
of proteins including hDlg, MAGI, and scribble [21,22]; this
region is not required for its interaction with or degradation of
p53 [23–25].
High-risk E6 and E7 together efficiently immortalize primary
human keratinocytes [26–28] and E6 alone immortalizes
human mammary epithelial cells [29]. E7 binds to the
retinoblastoma protein (pRb), disrupts cell cycle control, and
inactivates this tumor suppressor pathway [30,31]. Transgenic
mice have been used to dissect the roles of these genes during
tumorigenesis. While E7 was found to be involved in promoting
tumor formation, E6 plays a major role in tumor progression
[32].
Several cellular models show that continued expression of
E6 is necessary to maintain the transformed phenotype. Over-
expression of papillomavirus E2 protein represses expression
of E6 and E7 and induces HeLa cell senescence [33–35].
Decreased expression of E6 mediated by RNAi results in
growth arrest, senescence, and in some cases apoptotic cell
death of several HPV positive cervical cancer cell lines [36,37].
Because these activities are essential features of HPV-induced
infection and oncogenesis, inhibition of E6 function is an ideal
target for an anti-viral drug.
Using our previous pharmacophore for the E6AP charged
leucine helical motif [18], a new in silico screen was performed
to identify a novel series of compounds that can inhibit the
interaction between HPV-16 E6 and E6AP. A selection of
naturally occurring flavonoid analogs displayed the best
inhibitory activity and highest potency. We describe the activity
of two compounds: the naturally occurring flavonoid luteolin
and the novel flavone analog CAF-24. Both displayed a low
micromolar IC50 in our in vitro binding assay, elicited a potent
increase in p53 and p21Cip1/Waf1 protein, and decreased viability
of HPV positive cell lines. We present evidence that luteolin
can interact directly with HPV-16 E6. Docking analysis using
the recently resolved structure of HPV16 E6 [38] suggests that
these compounds bind in a hydrophobic pocket at the interface
between E6 and E6AP.
Results
Filter plate based HPV-16 E6/E6AP interaction assay for
lead conformation
To characterize potential E6 inhibitors, a robust in vitro assay
was developed to measure the interaction between HPV-16 E6
and E6AP. Although results from this assay have been
published previously [18,39], this is the first time we have
describe its development in detail. The core 70 amino acids of
the E6 binding region of E6AP (residues 371-440) [8] was
fused to bacterial alkaline phosphatase (BAP) in the MY101
vector [40]. In preliminary experiments, this fusion was more
stable and bound with higher affinity than a fusion of BAP with
the 18 amino acid α-helical core E6 binding motif in E6AP (data
not shown). Briefly, glutathione-bead bound GST-16 E6 was
immobilized on 96-well filter plates, incubated with free E6AP-
BAP fusion protein, and unbound E6AP-BAP fusion was
washed from the plates. Binding efficiency was determined
from the intensity of BAP activated chemiluminescence
remaining in each well.
To calculate the signal to background ratio, binding was
tested in the presence of GST-E6, GST alone, or in empty
wells. The signal from the E6AP-BAP fusion was 20-fold
greater in the wells with GST-E6 than in empty wells or those
containing GST alone. Binding was subsequently examined in
the presence of DMSO, the solvent present in the library, and
up to 20% DMSO was tolerated without loss of signal (data not
shown).
Kinetic analysis was performed to characterize the protein-
protein interaction inherent in this assay. The equilibrium
dissociation constant (Kd) of 139 nM was ascertained by a
saturation binding experiment (Figure 1A). This was more than
20-fold lower (i.e. tighter binding) than the value reported for a
smaller E6AP fusion that contains residues 403–417 [41]. The
off-rate (koff) was determined in a dissociation binding
experiment as 0.19 min-1 and the half-life of ligand dissociation
(t1/2) was calculated to be 3.6 minutes (Figure 1B). This
information confirmed that 1 hour incubations were sufficient
for the competitive binding assays to reach saturation.
To assess inhibition of this protein-protein interaction, an 18-
mer peptide derived from E6AP was used as a positive control
(Figure 1C) that corresponds to the α-helical leucine motif
necessary for the interaction between E6 and E6AP [15,42].
This peptide folds correctly [16], interacts with purified E6 by
NMR [43] and can directly compete with and disrupt the binding
between GST-E6 and E6AP-BAP. The E6AP proline mutant
E11P 18-mer was used as a negative control (Figure 1C)
[15,16]. This peptide has a proline substitution at the core of
the helical motif at position 11 that disrupts correct folding in
the peptide and does not interact with E6. The E6AP 18-mer
was an effective inhibitor of the interaction between E6 and
E6AP-BAP with an IC50 of 26 µM and inhibited binding by 95%
(16.6 fold) at 100 µM. The % deviation in the wells with the
DMSO control and E6AP peptide was 13% and 17%,
respectively.
By comparing the well-to-well variation with the magnitude of
change between control-treated and untreated cells, it is
possible to statistically determine a z’-factor for the assay. The
z’-factor mathematically assesses whether the changes in
signal intensity are significant and if the assay can accurately
distinguish “hits” from a large number of test compounds. An
assay with a z’-factor > 0.5 is appropriate for high throughput
screening (HTS). The z’-factor calculated for our test plates
was 0.53 with a signal to noise ratio of nearly 20:1 and can be
considered well suited for high content screening.
New in silico screen using a pharmacophore for the E6
interaction domain
We previously defined a six-point pharmacophore model for
the identification of compounds that bind to E6 [18]. It was
based on mutagenesis and three-dimensional data on LxxLL
E6-interacting helical motif, including the E6AP sequence
LQELLGE (L9-Q10-E11-L12-L13-G14-E15) [15,16]. This motif
Structure Based HPV16-E6 Inhibitors
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forms a helical domain with a hydrophilic surface that consists
of three leucines (Figure 2A; orange spheres) on one side of
the helix and charged surface on the other that includes the 2
glutamic acid residues (Figure 2A; purple spheres). In addition,
a zone of exclusion was defined to represent the lack of
reactive potential of glycine in position 14 (Figure 2A; gray
sphere).
For this study, four of the six points were combined
systematically to query the National Cancer Institutes (NCI)
open chemical and Synthline databases. The most successful
query included the two hydrophilic spheres at L12 and L13, the
hydrogen-binding sphere at E11, and the sphere of exclusion
at G14. Through a pharmacophore validation step, the precise
distances between each of the points and the contact radius of
each sphere was determined of the pharmacophore (Figure
2B) and adjusted iteratively to obtain a reasonable number of
virtual hits from the chemical collections (251 hits of roughly
250,000) (Figure 2B). The 251 hits were then used to perform
atom-atom similarity hits from a virtual library of 4.5 million
commercially available compounds to yield a set of 18,000
candidate molecules. Stochastic conformational analysis of the
18,000 molecules resulted in roughly 700,000 energetically
reasonable conformations for query using the pharmacophore.
Of the 714 compounds that best matched the pharmacophore,
72 were chosen for further evaluation based on expected
chemical stability, molecular weight, log P and log D scores,
price, and availability.
Confirmation of in silico leads
The collection of 72 available structural-lead compounds was
tested in the filter-plate based in vitro E6-E6AP binding assay.
Compounds were tested twice at concentrations of 10, 50, and
100 µM. Of these, 26 compounds inhibited the E6-E6AP
interaction by greater than 50%. The ten most active (inhibition
>75%) and reproducible inhibitors were retested in duplicate
using the in vitro binding assay at 5 concentrations ranging
Figure 1.  Kinetic Characterization of the in vitro GST-E6/E6AP-BAP Binding Assay.  (A) Saturation binding assay with GST-
E6 concentration at 500 ng per well (400 nM) while E6AP-BAP concentration was increased. (B) Dissociation rate experiment. GST-
E6 and E6AP-BAP were allowed to bind to equilibrium and unbound E6AP-BAP was washed from the wells. Dissociation was
measured as a decrease in BAP signal at each time point. (C) The E6AP 18-mer peptide inhibits the interaction between E6AP-BAP
and GST-16 E6. E11P peptide is unable to efficiently bind E6 and cannot compete with E6AP-BAP.
doi: 10.1371/journal.pone.0084506.g001
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Figure 2.  Pharmacophore design and novel flavonoid inhibitors.  (A) The pharmacophore is mapped on the three-dimensional
structure of the E6AP helical motif (PDB ID: 1EQX). The green α-helix corresponds to 18 amino acids of E6AP peptide. The
residues L9, E11, L12, L13, G14, and E15 are displayed. The orange hydrophilic spheres are superimposed over the leucines at
positions 9, 12, and 13. The charged spheres for positions 11 and 15 are presented in purple. The zone of exclusion around glycine
14 is represented by the gray sphere. (B) The distances between reactive groups were determined by the peptide structure of
E6AP. Ångström distances are listed in green. The initial radius of each sphere was calculated from the ensemble of structures of
the peptide. (C) Relevant compounds are listed. These include active compounds from the initial screen and novel flavonoid
derivatives synthesized for this project.
doi: 10.1371/journal.pone.0084506.g002
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between 5 to 250 µM. To confirm specificity, these compounds
were also assayed for the ability to disrupt either the interaction
between anti-FLAG antibody and the FLAG epitope in the
E6AP-BAP fusion. Compounds that disrupted the Flag-BAP
interaction with the same potency as the HPV-16 E6 and E6AP
interaction were classified as non-specific and eliminated from
further analysis.
The inhibitory potential of these compounds was confirmed
and the IC50 for each calculated. Of the ten compounds tested,
six did not produce a robust dose response in the E6-E6AP
binding assay. The four remaining compounds; 117, 160, 168,
and 170; did produce dose response curves with low
micromolar IC50 values (Figure 2C and 3). However, 117 and
160 also inhibited binding in the FLAG-E6AP assay and were
classified as non-specific inhibitors. The two remaining
compounds, 168 and 170, had a similar flavone scaffold and
inhibited the E6/E6AP interaction with an IC50 value of 44 µM
(Figure 3C,D). These compounds are the acetylated pro-drug
analogs of the naturally occurring flavonoids quercetin and
luteolin (Figure 2C). Compound 168 displayed some non-
specific inhibitory activity in the FLAG-E6AP. Compound 170
was the more selective inhibitor of the E6-E6AP interaction.
SAR from target-library of synthesized flavone
compounds
The 5,7-dihydroxy-4H-chromen-4-one core found in
compounds 168 and 170 was chosen as the lead chemotype
for initial structure activity relationship studies. A library of
nearly 70 additional flavonoid compounds was synthesized to
explore the chemical space around this scaffold and identify
more potent inhibitors of the E6-E6AP interaction. All new
compounds were first assayed in duplicate for inhibition of the
interaction between E6 and E6AP across a 5-point dose range
between 12.3 µM and 1 mM. Compounds were considered
active if they inhibited the interaction between E6 and E6AP by
at least 80% at a concentration equal to or less than 100 µM.
Active compounds were retested in a second round of filter
binding assays including the E6/E6AP-BAP assay, the
FLAG/BAP assay, and an additional specificity assay that
measures the interaction between GST-E6 and a fusion of
three PDZ domains of hDlg onto BAP (hDlg-BAP). This
interaction between E6 and hDlg occurs at the C-terminus of
E6 and is independent of the interaction between E6 and the
charged leucine helix in E6AP [21,22]. Compounds that directly
disrupt the interaction between E6 and E6AP-BAP should not
disrupt the interaction between E6 and hDlg-BAP, unless these
disrupt the folding and overall conformation of the E6 protein.
For this series, compounds were tested in quadruplicate at 7
concentrations ranging from 0.5 µM to 333 µM and were
classified by their inhibitory activity, potency and specificity.
In this library, the 5,7-dihydroxy-4H-chromen-4-one core was
held constant (Figure 2C). Upon re-synthesis, compound 170
displayed much lower activity and potency than observed with
the initial hit. However, systematic deacetylation of compound
170 revealed that the flavone luteolin was more active and
more potent, with up to 100% inhibition of the interaction
between E6 and E6AP and an IC50 of 4.3 µM in the full 7-point
binding assay (Figure 3E). Further analysis revealed that
modification of the free hydroxyl groups in luteolin, including
either methylation or acetylation, decreased both potency and
inhibition (Table S2). The fully methylated analog of luteolin,
CAF-8, demonstrated no activity in the initial binding assay
(Figure 3H). The one exception was methylation of the hydroxyl
group at position 5 in CAF-10 (Figure 2C, Table S2), which
displayed the same potency and activity as luteolin. Removal of
the hydroxyl groups at any position also resulted in progressive
loss of activity (Table S3). CAF-13 and CAF-14 (Figure 2C,
Table S3), which lack hydroxyl groups in the 7 and 3’ positions
respectively, produced a similar level of inhibition but their IC50
increased by 15-30 fold.
Identification of novel flavones with E6 inhibitor activity
A second branch of the medicinal chemistry effort focused on
4H-chromen-4-one as the core scaffold. A library of 160
compounds was generated without the hydroxyls on positions 5
and 7. As with the previous library, these compounds were
initially screened for the ability to inhibit the E6-E6AP
interaction by at least 80% at a concentration of 100 µM or
less. Active compounds were re-screened in the E6/E6AP,
FLAG/BAP, and E6/hDlg binding assays.
As discussed above, masking or removal of the hydroxyls in
positions 5 and 7 resulted in loss of inhibition in the in vitro
assay (Tables S1-S3). This was likely due to loss of hydrogen
bonding potential in this portion of the molecule. Addition of a
substituted benzene or heterocyclic B-ring at positions 6 or 7
restored activity (Figure 4). The B-rings in active compounds
included tetrazole, benzoic acid, pthalic acid, and carboxylic
acid. The addition of the B-ring supported similar levels of
activity and potency to luteolin, even in the absence of the
exposed hydroxyls at positions 3’ and 4’ as highlighted in the
SAR for luteolin. These compounds also displayed a higher
selectivity for inhibition of the E6/E6AP interaction than the
controls. Two of these compounds, CAF-24 and CAF-26, had
IC50 of 2.8 µM and 5.1 µM in the full dose response curves.
Each contained a tetrazole group at position 6 and displayed
activity similar to luteolin in the in vitro filter-binding assay but
had increased specificity against the FLAG and hDlg control
binding reactions (Figure 3F,G).
Confirmation in HPV-dependent cell culture models
A critical validation step was to confirm that the in vitro
inhibitors demonstrate activity in cell-based assays. Two cell
lines, one HPV positive and one HPV negative, were cultured
in the presence of increasing concentrations of luteolin or
CAF-24. Caski cells, which are derived from an HPV-16
infected cervical carcinoma and express HPV-16 E6 and E7,
were used to determine whether these compounds interfere
with HPV-16 E6 function. Inhibition of E6 should block its ability
to promote the degradation of p53 thereby increasing the levels
of p53. Treatment of Caski cells with each of these compounds
led to increased p53 levels and a concomitant induction of the
p53 responsive, cell cycle regulatory protein p21Cip1/Waf1 (Figure
5A). These compounds were also assayed in telomerase
immortalized human retinal epithelial cells (RPE-1). RPE-1
cells do not contain HPV DNA or express the E6 protein. If the
elevation in p53 is dependent on the inhibition of E6 by these
Structure Based HPV16-E6 Inhibitors
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Figure 3.  Activity of flavonoids in the in vitro binding assay.  Compounds were tested in vitro for the ability to disrupt the E6-
E6AP interaction. Increasing amounts of compound was mixed with purified GST-HPV-16 E6 and FLAG-tagged E6AP-BAP (red),
HPV-16 E6 and FLAG-tagged hDlg-BAP (green), or FLAG antibody beads and FLAG-tagged E6AP-BAP (blue). Percent inhibition
was determined by the amount of BAP activity remaining in the well after washing and normalized to DMSO. Data was plotted by
linear regression for single site binding using Prism (n=3, S.E.M.).
doi: 10.1371/journal.pone.0084506.g003
Structure Based HPV16-E6 Inhibitors
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e84506
compounds, p53 should not increase in the RPE-1 cells. With
luteolin, we did observe an increase in p53 protein levels, but
only at concentrations higher than was required to increase
p53 and p21 levels in the Caski cells (Figure 5B). This is not
unexpected as flavonoids such as luteolin have been identified
as potential anticancer and anti-proliferative agents in a wide
range of cancer cell lines [44–46]. Unlike luteolin, CAF-24 did
not induce increased levels of p53 or p21 proteins in the HPV
negative RPE-1 cell line (Figure 5B).
Figure 4.  Structure activity relationship of novel flavonoid compounds.  The table presents the potency and maximum
inhibition of the novel flavonoid compounds in the in vitro E6/E6AP filter binding assay. These compounds lack the hydroxyl groups
found on the B-ring of luteolin. These groups are replaced by a substituted benzene or heterocyclic B-ring at positions 6 or 7 to
reconstitute activity.
doi: 10.1371/journal.pone.0084506.g004
Structure Based HPV16-E6 Inhibitors
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Figure 5.  Compound activity in HPV positive cell lines.  Compounds were tested for the ability to induce p53 and p21Cip1/Waf1
expression in Caski (A), RPE-1 (B) E6/E7 immortalized human foreskin keratinocytes (HFKs) (C), and primary HFKs (D). Actin was
used as a loading control. Cells were incubated with compound for 40 hours.
doi: 10.1371/journal.pone.0084506.g005
Structure Based HPV16-E6 Inhibitors
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These data were corroborated using human foreskin
keratinocytes (HFK). Each compound was used to treat
primary HFKs or HFKs immortalized through the over-
expression of HPV16 E6 and E7 proteins [26]. In contrast to
the E6/E7 immortalized HFKs, primary HFKs should not be
dependent on E6 expression and should not demonstrate an
increase in p53 in response to treatment with E6 inhibitors. As
expected, both compounds increased p53 and p21 protein
levels in the E6/E7 immortalized HFKs (Figure 4C), although
CAF-24 was less potent. As seen with the RPE-1 cells, luteolin
promoted an E6 independent increase in p53 and p21 in the
primary keratinocytes (Figure 5D), whereas CAF-24 had little
effect on p53 and p21 levels (Figure 5D).
It is possible that the increased p53 and p21 levels resulted
from non-specific inhibition of protein degradation. However, if
the increase in p21 was dependent upon p53 promoter
activation, it should be possible to detect changes in the
amounts of p21 mRNA detected in treated cells. To confirm
that the increase in p21 protein level resulted from p53
activation, the levels of p21 mRNA were analyzed using qRT-
PCR. The increase in p21 mRNA observed with luteolin and
CAF-24 treatment mirrored the increase in p21 protein (Figure
6), supporting the hypothesis that the increase in p21 protein
resulted from an increase in the amount of p53.
HPV-18 positive HeLa cells and two additional control cell
lines, C33a, a cell line derived from an HPV-negative human
cervical cancer isolate, and HaCat, a spontaneously
immortalized human keratinocyte cell line, were used to assess
compounds for their impact on cell growth and viability. All cells
were incubated for 48 to 96 hours with increasing doses of
compound. Cell viability was measured by MTS based assay
and % viability quantified relative to cells treated with DMSO.
Luteolin was a potent inhibitor of Caski, E6/E7 HFKs, and HeLa
growth, but they also decreased viability in the control cell lines
(Figure 7A,C and Figure S1). This is in agreement with the lack
of specificity for HPV-dependent cells observed in the p53
western results. Specificity for HPV positive cells was observed
with CAF-24 treatment. CAF-24 selectively inhibited growth of
Caski, E6/E7 HFKs, and HeLa cells with little effect on the
viability of the HPV negative cell lines C33a, HaCat, and RPE1
(Figure 7B, D and Figure S1). CAF-24 did, to a lesser extent,
inhibit growth of the primary HFKs, but the difference in viability
between primary HFKs than E6/E7 HFKs was statistically
significant (Figure 7D, p< 0.05).
Senescence, cell morphology, and apoptosis
The increased p53 and p21 levels suggested that the
decrease in cell viability might be due to p53-induced
senescence or apoptosis. Caski, HeLa, RPE-1, C33a, and
HaCat cells were treated with luteolin or CAF-24 for 72 hours,
fixed, and stained for senescence associated beta
galactosidase (SA-β-gal) activity. Caski cells had low-level
basal β-gal staining in vehicle treated samples that increased
more than two-fold following treatment with CAF-24 (Figure
S2A). This was specific to Caski cells and was not observed in
RPE-1, HeLa cells, or the HPV negative control cell lines C33a
and HaCat (Figures S2A,B). Luteolin treatment caused a
dramatic decrease in the number of cells per well. As observed
Figure 6.  Induction of p21Cip1/Waf1 mRNA.  Compounds were tested for the ability to induce p21Cip1/Waf1 expression at the mRNA
level. Relative increases in transcripts were determined by qRT-PCR. Caski (black), RPE-1 (white), E6/E7 immortalized HFKs
(gray), and hTERT immortalized HFKs (light gray) cells were treated at 3 increasing concentrations of either CAF-24 or luteolin for
24 hours. Fold induction was calculated in relation to treatment with DMSO and normalized to GAPDH. Data were analyzed using
one-way ANOVA with post-hoc analysis (Dunnetts; S.E.M.; n=2). Statistical significance (p<0.01) is indicated as * in comparison to
Caski control (DMSO), # E6/E7 HFK control (DMSO), § HFK control (DMSO), and ◙ for RPE-1 control (DMSO).
doi: 10.1371/journal.pone.0084506.g006
Structure Based HPV16-E6 Inhibitors
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in the viability assay, this occurred in both the HPV positive and
negative cell lines. We observed no significant increase in β-gal
staining in any of the cell lines in the presence of luteolin. While
CAF-24 decreased Caski and HeLa cell numbers, no change in
cell morphology was observed in any cell type. Luteolin caused
severe morphological changes in most cell lines including
vacuole formulation in HeLa, Caski, C33a, and HaCat cells,
and the formation and extension of processes in RPE-1 culture
(Figure S2A; luteolin @ 50µM). These cell lines were also
assayed for apoptosis. Each was cultured in 96-well dishes in
the presence of CAF-24 or luteolin from 4 – 48 hours and
tested for activity of caspases 3 and 7. We did not observe
increased caspase activity with either compound at any time
point (data not shown).
In vitro p53 degradation
To confirm that these compounds inhibit the E6-dependent
degradation of p53 directly, luteolin, CAF-24 and CAF-8 were
tested by in vitro HPV-16 E6 mediated p53 degradation assay.
In vitro expressed p53 was incubated in rabbit reticulocyte
lysate in the presence or absence of in vitro expressed HPV16
E6. p53 levels were reduced in reaction containing E6 proteins
(Figure 8). This decrease in p53 was not observed when E6
proteins were pre-incubated with 100 µM luteolin. CAF-24
addition at both 10 and 100 µM also stabilized p53. Although
this effect was not as pronounced as the effect of luteolin, it
was consistent across both concentrations. CAF-8, the
tetramethyl ester of luteolin, did not alter E6 mediated p53
Figure 7.  Effects of E6 inhibitors on cell viability.  Compounds were tested for the ability to change cell viability. Caski (black),
HeLa (gray), and RPE-1 (white) cells were treated with either luteolin (A) or CAF-24 (B) for 72 hours. HFKs (white) or E6/E7
immortalized HFKs (black) were treated with luteolin (C) or CAF-24 (D) for 48 hours. Cell density was determined using Celltiter 96
AQueous one solution assay. Percent viability was determined for each sample relative to the DMSO treated control samples.
Viability in each HPV positive cell line was compared to an analogous HPV negative cell line to determine if the compounds
selectively inhibited growth in HPV positive cell lines. Caski and HeLa were compared to RPE-1 (A,B). E6/E7 HKFs were compared
to primary HFKs (C,D). Significance was determined by 2-way ANOVA (n=3; S.E.M.; p <0.5 =*, p<0.1= **, and p<0.05***).
doi: 10.1371/journal.pone.0084506.g007
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degradation, which is consistent with the observed absence of
activity in the E6/E6AP-BAP assay (Figure 3 and Table S2).
Direct binding between luteolin and E6
These compounds were identified on the basis of their
similarity to the pharmacophore for the charged leucine helical
E6 binding motif. To confirm a direct interaction between E6
and the compounds, a surface plasmon resonance binding
assay was used. These experiments were limited due to the
poor solubility of both luteolin and CAF-24 in simple aqueous
solution [47]. Luteolin was soluble in the appropriate buffers at
concentrations of less than 20 µM.
For this study, E6 was fused to a GB1-fusion tag (GBF) and
immobilized while luteolin was flowed through the cell at
concentrations ranging from 1.6-12.5 µM. A reference cell with
immobilized GBF was performed simultaneously for
background subtraction. As luteolin concentration increased,
the corresponding binding response increased (Figure 9A),
suggesting luteolin directly binds to E6 protein. While direct
binding was observed, the data could not be properly fit to
determine binding affinity.
Luteolin was also able to compete for direct binding with an
E6-binding peptide, E6apc2. The E6apc2 peptide was derived
from the third zinc finger of the Sp1 protein and incorporates 10
amino acids from the charged helical domain of E6AP
(LQELLGEER) at its C-terminus [17]. This peptide disrupts the
interaction between E6 and E6AP with an IC50 of 19 µM [17]. In
this experiment, E6apc2 was immobilized while E6apc1 control
(E6-non-binder) was immobilized in a reference cell. GBF-E6
pre-incubated with luteolin in a dose range from 1.6 - 12.5 µM
and was flowed as analyte solution. As the concentration of
luteolin increased, a lower response for E6 binding to E6apc2
was observed (Figure 9B) suggesting that luteolin directly
competed with the peptide for binding to GBF-E6.
Figure 8.  Activity of flavonoid derivates on HPV-16 E6 mediated p53 degradation in vitro.  Luteolin, CAF-24 and CAF-8 were
tested for in vitro activity to alter 16E6 mediated p53 degradation. (A) p53 signal intensities are expressed as fold increase over p53
control (DMSO). Data were analyzed using one-way ANOVA with post-hoc analysis (Dunnetts; S.E.M.; n=5). Statistical significance
(p<0.05) is indicated as * in comparison to p53 control (DMSO), # to p53 and 16 E6 (DMSO) and § to p53 and 16E6 (CAF-8; 10, or
100 µM). (B) Representative Immunoblot of p53 and 16E6.
doi: 10.1371/journal.pone.0084506.g008
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Figure 9.  Direct binding between luteolin and E6.  (A) In this SPR experiment, E6 was immobilized while luteolin was flowed
through the cell. (B) SPR competition experiments using immobilized E6 ligand (E6apc2 peptide) competing for binding E6 protein
(20 μM, pH 8) with various concentrations of luteolin.
doi: 10.1371/journal.pone.0084506.g009
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Effect of flavonoids derivatives on MBP-E6 protein
melting curve
A thermal shift assay was used to assess compound binding
to HPV E6. In this reaction, protein denaturation is measured
by an increase in fluorescence from Sypro Orange as it binds
to the newly exposed hydrophobic surfaces on the protein [48].
A protein stability curve is created as a measure of the rate of
protein unfolding. The relative fluorescence is plotted against
temperature and the melting temperature (Tm) is determined
by calculating the temperature of peak fluorescence. Ligand
binding can stabilize the protein and increase the Tm. The
thermal profile of MBP-E6 proteins was investigated to
determine if the flavonoid derivatives could stabilize MBP-E6
protein structure during heat-induced unfolding. The thermal
profile of MBP-E6 in assay buffer compared to DMSO (1.8%
v/v) revealed that DMSO shifted the Tm of MBP-E6 from 59.38
± 0.13°C to 59.0 ± 0.0°C (Figure 10A), which failed to reach
statistical significance. CAF-8, which did not inhibit the E6-
E6AP interaction in vitro (Figure 8), was unable to significantly
alter MBP-E6 melting temperature at the tested concentrations
(Figure 10C). Both CAF-24 and CAF-26 were able to shift
MBP-E6 Tm nearly 1°C at 25, 50 and 150 µM (Figure 10D,E),
indicating that these compounds bind to and stabilize MBP-E6
protein structure. Addition of luteolin had no effect on the Tm of
MBP-E6 (Figure 10B). The change in Tm (∆Tm) was plotted for
each compound and compared to DMSO (Figure 10F,G). Only
CAF-24 and CAF-26 had a significant effect on the Tm for MBP
E6.
Docking of flavones into the E6AP binding site on the
three dimensional structure of HPV16-E6
Luteolin, CAF-24, and the acetylated luteolin pro-drug were
docked as ligands onto the E6 structure (PDB ID: 4GIZ) [38]
using an induced-fit docking model in Schrödinger Maestro
[49,50] (Figure 11). Each compound was docked flexibly in the
center of the interaction space using a predefined grid in
GLIDE [51,52]. In preparation of docking, the crystal structure
of HPV E6 bound to the five amino acid residues of E6AP
(maltose-binding periplasmic protein was removed) was
minimized using the OPLS2005 force field. Ligands were
prepared using LigPrep and also minimized with the
OPLS2005 force field. For the induced-fit model, protein amino
acid conformation sampling was performed within 20Å of each
ligand, and the ligands were re-docked using the GLIDE XP
algorithm.
We compared the GLIDE scores (kcal/mol) for the selected
compounds with their inhibitory activity for HPV-16 E6 in the in
vitro binding assay. The lower the score, the higher the
predicted affinity between E6 and the compound. In this
analysis, luteolin has a GLIDE score of -8.52 kcal/mol and
appears to bind at the binding interface for the charged leucine
helix of E6AP. As would be predicted from our binding assay
analysis (Table S1), the GLIDE score for the luteolin pro-drug,
compound 170, was higher than that of luteolin. Despite having
an affinity for E6 that is similar to luteolin in the binding assay,
CAF-24 had a GLIDE score of -6.08. This would predict a less
active compound with a lower affinity for E6, but a possible
reason for this is discussed below. Each of the compounds
docks to the hydrophobic pocket in HPV-E6 that corresponds
to the residues L70, V62, and L67.
Discussion
An accurate structure of the LxxLL binding surface on
HPV-16 E6 was not available when we began these
investigations. Therefore, we chose to focus our efforts on the
structure of the LxxLL helical motif [15,16]. We previously
reported a pharmacophore derived from the three-dimensional
structure of the conserved LxxLL domain from the E6AP and
E6BP proteins could be used to identify peptidomimetic
compounds that disrupt the interaction between E6 and E6AP
and block the E6-dependent degradation of p53 [18]. This work
served as proof of principle but the identified compounds
lacked potency and were not tractable to chemical modification.
We report here the results of a second in silico screen using
the NCI collections using a more constrained four-point
pharmacophore. Hits were confirmed in a multiwell plate based
in vitro E6-E6AP binding assay and selected compounds were
entered into an iterative chemistry program to identify more
active and potent analogs using the E6-E6AP binding assay.
An early model of the full-length structure of E6 was derived
from the C-terminal half of the molecule [53]. This model was
based on the assumption that the two halves of E6, which each
contain a zinc binding motif, would adopt similar folds and form
a pseudodimer along hydrophobic patches in each half of the
molecule. However, this model was not able to fully explain
many HPV-16 E6 mutants that disrupted the interaction
between E6 and E6AP and the degradation of p53 [43]. A more
recent NMR analysis of a dimerization mutant of the full length
HPV-16 E6 protein has been determined [47]. The spectra
matched well with that of the individual N- and C- terminal
halves of the molecule, however conformations of the N-termini
of each half do not change in the full-length context and is
inconsistent with a previous pseudo-dimeric model [53]. The
authors proposed that E6 captures LxxLL charged helix
domains through its interaction with the exposed hydrophobic
patch on the surface of the molecule. This was consistent with
the structure of BPV1 in complex with the LxxLL domain of
paxillin [38,54].
The three-dimensional crystal structure of HPV-16 E6 in
complex with E6AP has now been determined [38]. The
authors predict key molecular contacts between E6 and the α-
helical motif of E6AP. Residues that appear to be involved in
this interaction include R10, V31, Y32, L50, R55, V62, L67,
Y70, I73, R102, and R131 (Figures 11 and 12). The residues at
positions 31,32, 50, 62, 67, 70, and 73 are part of the
hydrophobic surface at the E6/E6AP binding interface. The
arginine residues appear to interact with the outer, charged
face of the α-helical motif of E6AP. We propose that
compounds that bind to this surface in E6 can prevent its
association with E6AP and will inhibit E6-mediated p53
degradation. Such E6 inhibitors could be developed as HPV
antiviral therapies as well as potential treatments for HPV
related cervical cancer. We have identified a series of
flavonoids that can bind to E6, inhibit p53 degradation, and
decrease viability of HPV positive cell lines. Interestingly, other
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Figure 10.  Effect of flavonoid derivates on thermal stability of MBP-E6 proteins.  Melt curves of MBP-E6 proteins were
measured using Sypro Orange dye. MBP-E6 proteins were equilibrated with luteolin, (5-150 µM), CAF-8 (5-150 µM), CAF-24 (5-150
µM),CAF-26 (5-150 µM) or DMSO (1.8% v/v) followed by addition of Sypro Orange and fluorescence measurement in a real-time
PCR cycler. (A) Thermal fluorescence profile of MBP-E6 in assay buffer (square) or DMSO (triangle) along with assay buffer
(circle). Dose effect of luteolin (B), CAF-8 (C), CAF-24 (D), and CAF-26 (E) on MBP-E6 protein melt curves. Vertical dotted line
corresponds to MBP-E6 (DMSO) melting temperature. (F,G) Change of protein melting temperatures (∆Tm) of MBP-E6 by assay
buffer, luteolin, CAF-8, CAF-24 and CAF-26 over DMSO. Data were analyzed using one-way ANOVA with post-hoc analysis
(Dunnetts; S.E.M.; n=4). P<0.05 was considered as statistical significant and * indicates statistical significance compared to DMSO
treatment.
doi: 10.1371/journal.pone.0084506.g010
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Figure 11.  Induced-fit docking of flavone compounds with E6.  Starting from the crystal structure of HPV E6 bound to the
LXXLL peptide of E6AP (PDB ID: 4GIZ), luteolin (A), CAF-24 (B) and the acetylated analog of luteolin; Compound 170 (C) were
flexibly docked into E6 using the induced-fit docking model in Schrödinger Maestro, while allowing protein flexibility within a 10Å
radius of each ligand. Amongst the three flavone compounds, luteolin and CAF-24 docked in similar conformations and appear to
interact with E6 in a comparable fashion. Compound 170, however, was unable to bind in the same way as the other two
compounds, likely due to steric hindrance. The respective GLIDE score (kcal/mol) of each compound is shown for each docked
structure.
doi: 10.1371/journal.pone.0084506.g011
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naturally occurring flavonoids were identified as potential E6
inhibitors in an assay using caspase 8 binding to HPV-16 E6
[55].
Luteolin, CAF-24, and CAF-26 disrupted the interaction
between E6 and E6AP in the in vitro binding assay with low
micromolar IC50 values (Figure 3). The tetramethyl analog of
luteolin, CAF-8, was inactive in this assay. This appears to be
due to loss of hydrogen bonding potential by masking of the
hydroxyls in the A’ and B rings of the flavone scaffold. The
inhibition of the interaction of E6 and E6AP correlated with a
decrease in E6-dependent degradation of p53 in vitro (Figure
8). Luteolin and CAF-24 prevented p53 degradation in this
Figure 12.  Flavone compound docking and pharmacophore comparison.  (A) Illustration of E6AP (green helix) binding to
HPV16-E6 (PDB ID: 4GIZ). Important residues in E6 are highlighted. Hydrophobic residues are gray, and selected arginine residues
are blue. The residues included in our pharmacophore (L9, E11, L12, L13, G14, and E15) are labeled. Leucines are orange,
glutamic acids are purple, and glycine is gray. CAF-24 and luteolin are overlaid on this model. (B) Using the docking models and the
positioning of the E6AP helix, luteolin (C) and CAF-24 (D) are docked on to the six-point E6-binding pharmacophore. Each of the
compounds makes contact with 4 of the 6 interaction spheres defined in this model, E11, L12, L13, and G14.
doi: 10.1371/journal.pone.0084506.g012
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assay, while CAF-8 displayed no inhibitory activity. These
observations translated well to studies in HPV-positive cell
lines (Figures 5-7 and Figures S1,S2). CAF-24 increased p53
levels and decreased cell viability in HPV positive cell lines.
Luteolin also increased p53 levels and decreased cell viability
but lacked specificity and displayed off-target toxicity in HPV
negative cells.
In surface plasmon resonance assays, luteolin bound directly
to E6 and displaced the E6AP helical motif from its complex
with GBF-E6 (Figure 9). Due to limited aqueous solubility
CAF-24 and CAF-26 could not be screened in this assay.
There was also a strong correlation between E6 inhibition in
vitro and MBP-E6 stability in thermal shift assays. The novel
flavones CAF-24 and CAF-26 increased the Tm of MBP-E6 by
about 1°C (Figure 10), while CAF-8 had no measurable effect.
While luteolin was tested in this assay, it did not shift the Tm of
MBP-E6. The disagreement between SPR and thermal shift
data may be explained by the small size and potential lack of
specificity of luteolin. The affinity of luteolin for the E6AP
interaction surface and stabilizing effect on MBP-E6 folding
may be too small to detect. It is also possible that the hydrogen
bonding potential of luteolin may allow it to bind equally in
native and unfolded states thus masking any shift in Tm.
The compounds luteolin, 170, and CAF-24 were virtually
docked onto the three-dimensional structure of E6 using the
induced-fit docking model in Schrödinger Maestro [49,50]. This
analysis predicted that the compounds bind in a hydrophobic
pocket at the interface between E6 and E6AP (Figure 11). It is
interesting to note that in Figure 11C the tetrazole group of
CAF-24 extends into a pocket created between R131 and I104
in E6. This additional group may restrict CAF-24 from binding
to off-target hydrophobic sites and explain the difference in
specificity between luteolin and CAF-24. It is noted, however,
that these compounds did not quantitatively rank with their
respective experimental IC50 values when compared to one
another, as can be seen with their respective GLIDE scores
(Figure 11). This could be explained by the observation that
tetrazole-containing compounds would often adopt alternative
orientations in the E6AP binding site on E6 when interrogated
using GLIDE. Ionized tetrazole groups would orient towards
L100, potentially indicating the presence of multiple possible
modes of binding. This factor would not be represented in a
compound’s IC50 score as it could still bind at the site of
interaction and disrupt E6-E6AP binding, regardless of its
affinity for a particular orientation at that site. Although tetrazole
functional groups are likely to be ionized at physiological pH,
this does not necessarily preclude their protonation and binding
in the orientation as depicted in Figure 11C.
By overlaying the docking models for luteolin and CAF-24
with the resolved structure for HPV16-E6 bound to the E6AP α-
helical motif, we can visualize how the compounds fulfill the
molecular contacts defined by the pharmacophore (Figures 2
and 12). Luteolin and CAF-24 dock in the hydrophobic pocket
and are oriented so that the A and A’ rings fill the same space
as the leucines on positions 9, 12, and 13 of the E6AP helix
(Figure 12A). Based on the docking model neither of the
compounds mimics the charged groups represented by the
glutamic acid residues at positions 11 and 15. This observation
is visualized down the axis of the helix (Figure 12B).
The resolved structure predicts that the glutamic acid at
position 16 of E6AP interacts directly with the arginine at
residue 10 in E6 [38]. In this structure, the E15 residue of E6AP
projects out and away from the binding surface on E6AP and
does not appear to be involved in binding. The glycine at
position 14 allows the E6AP helix to pack between the
arginines at positions 131 and 10 in E6. The flexibility at this
position may also promote the interaction between the E16 of
E6AP and R10 in E6. Neither compound extends into the
exclusion sphere for G14.
Based on this docking, our compounds match 4 of the six
points in our pharmacophore at L9, L12, L13, and G14, thus
reproducing 4 of the 6 contacts points in the LxxLLG core of
the helical ‘charged leucine’ motif. If this model is correct, it is
possible that the flavone core could be used as an anchor and
reactive groups could be added to promote interaction with the
arginine residues at positions 10 and 131. Not only would such
compounds have increased affinity and specificity for E6, but
the hydrophilic nature of such groups could also act to repel the
hydrophobic surface of the charged leucine helix of E6AP and
increase the potency of these compounds.
CAF-24 has a tetrazole in position 6. This substituent does
not disrupt the binding but rather seems to increase specificity.
The tetrazole group can act as a bioisostere of carboxylic acid
[56] and may serve for additional contacts on E6; however, it is
possible that the addition of the tetrazole increases the water
solubility of the ligand, thus resulting in favorable changes in
solvation/desolvation energies. In the docking model for
CAF-24 shown in this study, the tetrazole group fits into a
pocket between I104 and R131 (Figure 11C). The size of this
group may sterically hinder binding to proteins other than E6
and could be responsible for its increased specificity. Other
novel flavone analogs have bulky substituents at either position
6 or 7 and maintain inhibitory activity (Figure 4). We are
continuing to explore the benefit of including such groups while
attempting to increase the potency, activity and specificity of
these compounds.
The minor structural differences within this compound series
accounts for dramatic changes in specificity. While the natural
compounds, including luteolin, may prove valuable as chemical
probes for studying the role of HPV E6 in cell models, the off-
target effects in HPV-negative cells lines rules these out as
candidates for therapeutic intervention in HPV infection and
cervical cancer.
There is no antiviral treatment for HPV infection. Current
therapies for cervical dysplasia and cancer involve destruction
or removal of the infected tissue by cytotoxic agents or surgery.
While therapeutic HPV vaccines have been considered,
efficacy in the anecdotal trials has been modest at best.
Prophylactic HPV vaccines are very effective, nonetheless,
there are major socioeconomic challenges to worldwide
implementation, acceptance, and use of an expensive vaccine
program. Moreover, the prophylactic HPV vaccine offers no
benefit for the millions of women and men already infected with
HPV. Because of the long latency between existing HPV
infection and malignancy, a measurable reduction in cervical
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cancer will not occur for at least 10 years. The therapeutic
intent of this project takes advantage of the fact that
progression from dysplasia to malignancy occurs over several
years, providing a window of opportunity for an effective
medical treatment.
These studies should lead to the identification new chemical
probes of the conserved regions within the LxxLL/E6
interaction surface, thereby illustrating druggable targets on the
high-risk E6 proteins, and drive our current E6 inhibitor
optimization program.
Materials and Methods
Definition of the pharmacophore and in silico screening
The pharmacophore used in this study is the E6AP model
[18] and defines the spatial orientation of reactive groups in the
E6AP helix, specifically L9, E11, L12, L13, G14, and E15.
These are represented by three hydrophilic points (L9, L12,
and L13), two hydrogen-binding points (E11 and E15), and an
exclusion sphere (G14) (Figure 2A). Unlike the previous report,
which queried all 6 points in the pharmacophore, in this study
sets of 4 points in the pharmacophore were compared to
generate reasonable numbers of hits. In silico screening was
otherwise performed as described previously except that both
NCI and Synthline databases were queried [18].
Expression and purification of GST-E6 and BAP fusion
proteins
GST-E6.  Expression – A 10 mL overnight starter culture of
GST-E6 expressing bacteria (BL21) was transferred to 1L
TurboBroth and grown at 37°C until it reached an O.D. of ~0.5.
Cultures were induced overnight at 28°C with 0.2 mM IPTG
and 0.3 mM lactose. Cells were pelleted at 6000x g and lysed
in 50 ml of lysis buffer. Lysis buffer contained 100 mM Tris pH
8.0, 100 mM NaCl, 0.1% NP-40, 5.0 mM DTT, and 1 x
protease inhibitor cocktail (EDTA free, Sigma). Cells were
sonicated 6 times; 10 sec. ON and 30 sec OFF; at an
amplitude of 40%. Lysates were cleared at 15,000x g for 30
minutes and transferred to a new tube. Purification – 1 mL of
50% glutathione bead slurry (GE Healthcare Life Sciences,
Glutathione Sepharose 4 Fast Flow) was added to the lysate
and incubated overnight at 4°C with inversion. Beads were
collected by centrifugation at 500xg for 5 minutes and kept on
ice. Beads were washed 4 times for 10 minutes with inversion
at 4°C in ice cold lysis buffer without NP-40. After final wash,
transfer to 1.5 mL tube and store in lysis buffer without NP-40.
GST-E6 proteins were kept at 4°C for no more than 1 week.
BAP fusions.  Expression – A 10 mL overnight starter
cultures of BAP fusion expressing bacteria (BL21) were
transferred to 1L TurboBroth and grown at 37°C for 3-4 hours.
No induction was required. Cells were pelleted at 6000x g,
lysed in 50 ml of lysis buffer, and sonicated as described
before. Lysates were cleared at 15,000x g for 30 minutes and
transferred to a new tube. Purification – 250 µL of anti-flag
resin (Sigma A2220) was added to the lysate and incubated
overnight at 4°C with inversion. Beads were collected by
centrifugation at 500xg for 5 minutes and kept on ice. Beads
were re-suspended in lysis buffer without NP-40 and
transferred to an Econocolumn (BioRad). The beads were
washed with 20 mL of ice cold lysis buffer without NP-40.
E6AP-BAP was released from the column by 5 successive
elutions with 250 µL of ice cold 0.2 M glycine pH 2.5 directly
into 250 µL of neutralization buffer [50% glycerol, 200 mM
NaCl, 200 mM Tris pH 7.5, 2x EDTA free protease inhibitor
cocktail (Sigma)]. BAP fusion proteins can be maintained at
4°C for < 2 weeks.
In vitro filter binding assay
Pre-Block - 96-well filter plates were prepared (0.2 µm
BioTrace NT, Pall). 100µL of blocking buffer (100 mM Tris pH
8.0, 100 mM NaCl, 0.1% milk) was added per well. Plates were
blocked for 1 hr at RT on an orbital shaker. Buffer was
removed by vacuum filtration using a vacuum manifold. GST-
E6 Bead addition – GST-E6 beads were prepared at 5µg/mL in
GST-E6 bead buffer (100 mM Tris pH 8.0, 100 mM NaCl, 0.1%
milk, 2.5 mM DTT). 100µL of GST-E6 bead mix was added per
well and incubated for 1 hr at 4°C. Buffer was removed by
vacuum filtration. Binding Reaction – E6AP or hDlg BAP
fusions were diluted to 50 nM or 25 nM respectively in binding
buffer (100 mM Tris pH 8.0, 100 mM NaCl, 1 mM DTT). 48 µL
of each reagent was added per well. For drug assay, 2µL of
compound was added to each well and mixed thoroughly. The
final reaction volume was 50 µL with 4% DMSO per well, which
is well below the acceptable limits for DMSO in our binding
assay. Plates were incubated for 1-3 hours at RT on an orbital
shaker. Buffer was removed by vacuum filtration. Plates were
washed on the vacuum manifold, first with 200 µL buffer (100
mM Tris pH 8.0, 100 mM NaCl, 1 mM DTT), and twice more
with 100µL lysis buffer without DTT. Plates were cleared and
dried with on the vacuum manifold. Assay – Immunostar assay
reagent was prepared and equilibrated to RT prior to addition.
60 µL of Immunostar-AP assay reagent was added, the BAP
activity was allowed to develop for 10 minutes and the plates
were read on a Wallace Luminometer. BAP activity was
measured as relative light units (RLU) on a luminometer using
the Immunostar-AP substrate (BioRad).
Cell culture
Caski (ATCC CRL-1550), HeLa (ATCC CCL-2), C33a (ATCC
HTB-31), and HaCat [57] cells were incubated in DMEM with
10% fetal bovine serum (Atlas). RPE-1 (ATCC-CRL-4000) cells
were cultured in DMEM/F-12 with 10% FBS. HFKs, E6/E7
immortalized HFKs [26], and hTERT immortalized HFKs were
cultured in Keratinocyte-SFM media (Life technologies,
17005-042).
p53/p21 analysis
20,000 cells per cm2 were plated in 6-well dishes. Cells were
incubated for 24 hours at which time fresh media and
compound were added. After 40 hours, cells were harvested,
washed with cold PBS, and lysed in RIPA buffer with protease
inhibitor. Each sample was separated on a 12% SDS-page gel,
transferred to Immobilon-P membrane (Millipore) and blotted
for the p53 (DO-1, Santa Cruz), p21 (c-19, Santa Cruz), and
actin (A2066, Sigma). Protein quantification was performed
with the Fujifilm LAS-4000 Multifunctional Imaging System. The
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signal intensity was measured for each band on an
immunoblot, normalized to the loading control, and the fold
increase was determined in relation to the appropriate DMSO
treated control. RNA was isolated from these cells using Trizol
Reagent (Invitrogen 15596-026). cDNA was generated using
the Improm-II Reverse Transcription System (Promega A3801).
qPCR was performed as described in the protocol for SsoFast
EvaGreen supermix (BioRad 172-5023) using an BioRad
CFX96 real-time PCR machine. Melting curves for each
reaction were obtained. Each sample was assayed in triplicate
and every plate contained a 5-point cDNA dilution course to
calculate amplification efficiency for each primer pair. The Pfaffl
method was used to determine the change in transcript levels
relative to the DMSO and normalized to GAPDH.
p53 in vitro degradation assay
p53 and E6 were in vitro translated using TNT® SP6 High-
Yield Wheat Germ (Promega) according to manufacturer's
instructions, as wheat germ does not contain E6AP proteins
[10,29]. In vitro translated E6 proteins (1µL) were incubated
with DMSO (2% v/v), Luteolin (10 µM, 100 µM), CAF-24 (10
µM, 100 µM) and CAF-8 (10 µM, 100 µM) in reaction buffer (25
mM Tris-HCl pH 7.5, 100 mM NaCl, 3 mM DTT, 2.5 mM ATP)
at 30°C for 1 hr. Control reactions (no DNA, p53 alone) were
incubated with 1 µL wheat germ extract and 2% DMSO in
reaction buffer. In vitro translated p53 and rabbit reticulocyte
lysate (RRL, Promega) were added to all reactions except the
no DNA control reaction to which wheat germ extract was
added instead of p53. Reactions were incubated for 3 hrs at
30°C and stopped by addition of 6X reducing SDS sample
buffer and heating at 95°C for 5 min. Each reaction was loaded
onto a 10% SDS-PAGE gel and transferred onto PVDF (0.45
µm). p53 and 16E6 were visualized using monoclonal p53
(Pab1801, 1:1000), monoclonal 16E6 (813, Arbor Vita
Corporation, 1:4000) antibody and anti-mouse HRP-labeled
secondary antibody (1:2000, Sigma-Aldrich).
Thermostability assay
MBP-16E6 DNA, a kind gift from G. Travé [58], was
transformed into BL21DE(3) E. coli. Protein expression was
performed by inoculation of a 1 mL starter culture in 100 mL of
Turbo-Broth containing 0.2 % lactose, 0.05% glucose and 0.6%
glycerol at 20°C for 24 hrs. Cells were lysed in 50 mM Tris HCl
pH 6.8, 300 mM NaCl, 0.1 % (v/v) NP-40, 2 mM DTT and 1x
protease inhibitor cocktail (EDTA-free, Roche) and sonicated
as described before. Cell lysate was cleared by centrifugation
at 15000xg, 4°C for 30 min and equilibrated with amylose resin
beads (New England Biolabs, Inc.) by inversion for 3 hrs at
4°C. Bound beads were washed one time in lysis buffer and
four times with wash buffer (50 mM Tris-HCl pH 6.8, 400 mM
NaCl, 2 mM DTT, 1x protease inhibitor cocktail). Bound MBP-
E6 proteins were eluted using a final concentration of 20 mM
maltose in 5 bed volumes of wash buffer. All steps were
performed at 4°C. Protein concentration was measured by BCA
(BioRad). Thermostability of MBP-E6 proteins was analyzed at
a final concentration of 1 µM in reaction buffer (50 mM TrisHCl
pH 6.8, 400 mM NaCl, 2 mM DTT). MBP-E6 proteins were
equilibrated with CAF-8 (5 µM-150 µM), CAF-24 (5 µM-150
µM), CAF-26 (5 µM-150 µM) or DMSO for 30 min in reaction
buffer. Sypro Orange, a hydrophobic fluorescent dye, was
added at the end of the incubation period at a final
concentration of 5X. The final DMSO concentration (1.8% v/v)
was kept constant across the concentration range.
Fluorescence was measured using the FRET channel of
CFX96 Real-Time PCR thermal cycler (BioRad) over a
temperature range of 25°C to 95°C. Temperature increments
were set to 0.5°C for 30 sec followed by plate reading. Melt
curves were determined in triplicate and repeated four times.
Melt curves represent the relative fluorescence of the 1st
derivative of four experiments. Melting temperature (Tm) was
calculated by CFX manager software. The average melting
temperature of the triplicate was used to calculate the ∆Tm for
each experiment. ∆Tm values are expressed as the change vs.
DMSO.
Cell viability and caspase assays
For cell viability, 12,000 cells per cm2 were plated in 96-well
dishes 24 hours prior to drug addition. Fresh media and
compound were added. Plates were read after 72-96 hours.
Relative cell viability was assayed as directed in the Celltiter 96
AQueous one solution assay (Promega). For caspase activity,
plates were assayed after 4, 8, 12, 24, or 48 hours as
described for the Caspase-Glo 3/7 assay (Promega).
SA-beta-gal assays
12,000 cells per cm2 were plated in 24-well dishes; after 24
hours, fresh media and compound were added. SA-beta gal
staining was performed as described [59]. Images were
collected using bright field microscopy. At least four fields
(~100 cells per field) were read for each treatment, and
experiments were repeated 3 times. The percent SA-beta-gal
positive cells was calculated for each data point.
Surface plasmon resonance
SPR analysis was performed on a Biacore 3000 instrument.
Immobilized GBFE6 [43] was diluted to 30μg/mL in 10 mM
sodium acetate, pH 4.0 and 5.0 and immobilized onto the
dextran matrix of a CM5 sensor chip (Biacore) using the amine
coupling method. All binding experiments were performed at 25
°C in 50 mM phosphate (pH 6.5) containing 200 mM NaCl.
Pulses of 10 mM glycine (pH 3.0) were used to regenerate the
surfaces between injections. A 33-mer peptide, E6apc2 that
binds E6, and a 29-mer peptide, E6apc1 that does not bind E6,
were used as controls and are characterized previously [17].
SPR data were analyzed using BIAevaluation 4.1 software
(Biacore).
Supporting Information
Figure S1.  Compounds were tested for the ability to alter
cell viability. Caski (black), HeLa (gray), RPE-1 (white), C33a
(diagonal hash) and HaCat (crosshatch) cells were treated with
either luteolin (A) or CAF-24 (B) for 72 hours. Cell density was
determined using Celltiter 96 AQueous one solution assay.
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Percent viability was determined for each sample relative to the
DMSO treated control samples.
(TIF)
Figure S2.  (A) For senescence associated βgalactosidase
assays, HPV positive (Caski) and negative (RPE-1) cell
lines were grown in the presence of CAF-24 or luteolin for
72 hours. Cells were fixed and stained for SA-β-gal activity.
(B) Senescence associated β-galactosidase assay results were
quantified and are plotted as percent β-galactosidase positive
cells. Additional data for β-galactosidase staining in C33a,
HeLa, and HaCat are included.
(TIF)
Table S1.  Role of acetylation on activity and potency.
(TIFF)
Table S2.  Role of methylation on activity and potency.
(TIFF)
Table S3.  Role of the hydroxyls on activity and potency.
(TIFF)
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